Grant ID DP240243
Awarded On May 15, 2024
Title Phase 1 Trial of Highly Potent Allogeneic G-NK Cells for Treatment of Multiple Myeloma and Non- Hodgkin's Lymphoma
Program Product Development Research
Award Mechanism Texas Therapeutics Company Awards for Product Development Research
Institution/Organization Indapta Therapeutics
Principal Investigator/Program Director Mark Frohlich
Cancer Sites Lymphoma, Myeloma
Contracted Amount $4,500,000*

*Pending contract negotiation

Lay Summary

This study focuses on an allogeneic cellular immunotherapy to treat cancer. Indapta, a Houston-based biotech company, has identified a highly potent subset of natural killer (NK) cells, g-NK cells, that it can expand from healthy donors. Indapta's g-NK product, IDP-023, has great potential to be a significant medical breakthrough in treating patients with advanced non-Hodgkin's lymphoma (NHL) and multiple myeloma (MM) who have few therapeutic options and are not candidates for autologous cellular therapy. Recent approved treatments (CAR-T, T cell engagers) have limitations: lack of durability, significant toxicities, and manufacturing delays. IDP-023 is an "off-the-shelf" cryopreserved pro...

Read More